Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction

Dario Cattaneo, Agostino Riva, Emilio Clementi, Laura Milazzo, Cristina Gervasoni

Research output: Contribution to journalArticle

Abstract

ABSTRACT: The combination of ombitasvir, dasabuvir and paritaprevir/ritonavir (referred as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here we describe an HIV-HCV coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the ATV plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an ATV dose reduction guided by therapeutic drug monitoring.

Original languageEnglish
Pages (from-to)285-287
JournalTherapeutic Drug Monitoring
DOIs
Publication statusPublished - 2016

Fingerprint

Hyperbilirubinemia
HIV
Ritonavir
Drug Monitoring
Hepacivirus
Antiviral Agents
Atazanavir Sulfate
Therapeutics
ABT-450
Sustained Virologic Response
ABT-333
ABT-267

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction. / Cattaneo, Dario; Riva, Agostino; Clementi, Emilio; Milazzo, Laura; Gervasoni, Cristina.

In: Therapeutic Drug Monitoring, 2016, p. 285-287.

Research output: Contribution to journalArticle

Cattaneo, Dario ; Riva, Agostino ; Clementi, Emilio ; Milazzo, Laura ; Gervasoni, Cristina. / Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction. In: Therapeutic Drug Monitoring. 2016 ; pp. 285-287.
@article{5898686a229b4332bf84fd4266f098fb,
title = "Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction",
abstract = "ABSTRACT: The combination of ombitasvir, dasabuvir and paritaprevir/ritonavir (referred as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here we describe an HIV-HCV coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the ATV plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an ATV dose reduction guided by therapeutic drug monitoring.",
author = "Dario Cattaneo and Agostino Riva and Emilio Clementi and Laura Milazzo and Cristina Gervasoni",
year = "2016",
doi = "10.1097/FTD.0000000000000293",
language = "English",
pages = "285--287",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction

AU - Cattaneo, Dario

AU - Riva, Agostino

AU - Clementi, Emilio

AU - Milazzo, Laura

AU - Gervasoni, Cristina

PY - 2016

Y1 - 2016

N2 - ABSTRACT: The combination of ombitasvir, dasabuvir and paritaprevir/ritonavir (referred as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here we describe an HIV-HCV coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the ATV plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an ATV dose reduction guided by therapeutic drug monitoring.

AB - ABSTRACT: The combination of ombitasvir, dasabuvir and paritaprevir/ritonavir (referred as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here we describe an HIV-HCV coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the ATV plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an ATV dose reduction guided by therapeutic drug monitoring.

UR - http://www.scopus.com/inward/record.url?scp=84959224250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959224250&partnerID=8YFLogxK

U2 - 10.1097/FTD.0000000000000293

DO - 10.1097/FTD.0000000000000293

M3 - Article

AN - SCOPUS:84959224250

SP - 285

EP - 287

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

ER -